Why the study?
Do ACE inhibitors or ARBs reduce new-onset atrial fibrillation, cardioversion failure, and atrial fibrillation recurrence?
Do ACE inhibitors or ARBs reduce new-onset atrial fibrillation, cardioversion failure, and atrial fibrillation recurrence?
Inhibitors of the renin-angiotensin system may significantly reduce the risk of new-onset atrial fibrillation, cardioversion failure, and post-cardioversion recurrence.
No takes yet. Share an insight, caveat, or question.
Supports ACEI/ARB consideration for AF prevention in eligible patients; extends meta-analytic evidence but warrants dedicated RCTs.
Kalus et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: